RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $200

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $215 to $200.

Benzinga · 12/23/2019 13:37

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $215 to $200.